Eli Lilly's Emgality drug failed to demonstrate statistical superiority over Pfizer's Nurtec in the CHALLENGE-MIG trial. The proportion of patients experiencing a 50% reduction in migraine headache days per month was statistically similar between the two drugs, although Emgality did achieve clinically meaningful efficacy and safety outcomes compared to a placebo. The CHALLENGE-MIG study is the first head-to-head comparison of two calcitonin gene-related peptide (CGRP) antagonists. Both Emgality and Nurtec belong to a class of CGRP antagonists that target the CGRP molecule, which induces inflammation in the brain causing painful migraines.
The results of this trial are disappointing for Eli Lilly as they hoped to establish their drug as superior to Pfizer's Nurtec. However, both drugs achieved similar response rates and had consistent safety profiles. This head-to-head comparison highlights the potential benefits of CGRP antagonists for treating migraines and may encourage further research into these types of treatments.
Keywords: Eli Lilly, Emgality, Pfizer, Nurtec, CHALLENGE-MIG trial. In a recent clinical trial called CHALLENGE-MIG, Eli Lilly